DOC1021
Glioblastoma (GBM)
Key Facts
About Diakonos Oncology
Diakonos Oncology is pioneering a novel dendritic cell vaccine (DCV) platform based on a discovery of a new immunological pathway. Its lead program, DOC1021, is in Phase 2 trials for glioblastoma (GBM) and Phase 1 for pancreatic adenocarcinoma, showing promising early results. The company, which operates as a private entity, leverages research from the Texas Medical Center and collaborates with leading institutions like Baylor College of Medicine and MD Anderson. Its approach focuses on addressing critical unmet needs in aggressive, late-stage cancers with poor prognoses.
View full company profileAbout Diakonos Oncology
Diakonos Oncology is pioneering a novel dendritic cell vaccine (DCV) platform based on a discovery of a new immunological pathway. Its lead program, DOC1021, is in Phase 2 trials for glioblastoma (GBM) and Phase 1 for pancreatic adenocarcinoma, showing promising early results. The company, which operates as a private entity, leverages research from the Texas Medical Center and collaborates with leading institutions like Baylor College of Medicine and MD Anderson. Its approach focuses on addressing critical unmet needs in aggressive, late-stage cancers with poor prognoses.
View full company profileTherapeutic Areas
Other Glioblastoma (GBM) Drugs
| Drug | Company | Phase |
|---|---|---|
| DB102 (Enzastaurin) | Denovo Biopharma | Phase 3 |
| GlioGuard Therapeutic & Diagnostic System | GlioGuard | Pre-clinical |
| Lead CAR-T Program | Kiragen Bio | Pre-clinical |
| GBM Immunotherapy (with SandboxAQ) | iOncologi | Pre-clinical |
| DCVax®-L | Northwest Biotherapeutics | Phase 3 |
| Lucicebtide (ST101) | Sapience Therapeutics | Phase 2 |
| Glioblastoma Assay Optimization (CPRIT Grant) | SingleCell Biotechnology | Pre-clinical |
| Lead Program (unspecified) | BlueHaven Therapeutics | Preclinical |
| TLX101 (Pixclara® / 131I-IPA) | Telix Pharmaceuticals | Phase 3 |
| Paxalisib | Kazia Therapeutics | Phase II/III |